Swiss pharmaceutical company Roche has reported positive data from the Phase III INAVO120 clinical trial of its investigational therapy, inavolisib, alongside palbociclib (Ibrance) and fulvestrant to treat locally advanced or metastatic breast cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,